Results 11 to 20 of about 59,932 (250)

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses [PDF]

Lancet, The, 2022
Background The Solidarity trial among COVID-19 inpatients has previously reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and interferon (IFN)-beta 1a were discontinued for futility but randomisation
Abdool Karim Q., Abi Hanna P., Abutidze A., Ader F., Al Mawali A., Al-Bader A., Alejandria M., Alhasawi A., Allum E., Alotaibi A., Alvarez- Moreno C., Appadoo S., Arts D., Asiri A., Aukrust P., Barratt-Due A., Beaumont H., Bellani S., Benassi V., Bhargava B., Branca M., Cappel-Porter H., Cerrato N., Cheick Haidara F., Como N., Eustace J., Gabunia T., Garcia P., Genetu Bayih A., Godbole S., Gotuzzo E., Griskevicius L., Hamra R., Hassan M., Hassany M., Henao-Restrepo A. -M., Hernandez Garcia C., Hutton D., Irmansyah I., Jancoriene L., John-Arne R., Khamis F., Kirwan J., Kumar S., Lopardo G., Lydon P., Magrini N., Malekzadeh R., Manevska S., Manuel O., Marie-Paule K., McGinty S., Medina M., Mesa Rubio M. L., Miranda Montoya M. C., Murthy S., Nel J., Nunes E., Pan H., Perola M., Peto R., Portoles A., Preziosi M. -P., Rasmin M., Raza A., Reddy K. S., Rees H., Reges P., Rogers C., Roses Periago M., Ryan M., Salami K., Salvadori M., Sathiyamoorthy V., Sauermann M., Sinani N., Soo Chow T., Sow S., Sterne J. A. C., Stevanovikj M., Swaminathan S., Tacconelli E., Tavares Maltez F. M., Teferi M., Tikkinen K., Trelle S., Tsertsvadze T., Zaid H.   +87 more
exaly   +10 more sources

Compassionate Use of Remdesivir for Patients with Severe Covid-19

New England Journal of Medicine, 2020
Background Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. Methods We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness ...
Erika Asperges, Antonella Castagna, Emanuele Nicastri   +2 more
exaly   +4 more sources

Remdesivir [PDF]

Hospital Pharmacy, 2021
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Terri L. Levien, Danial E. Baker
  +8 more sources

Remdesivir

Reactions Weekly, 2023
Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus ...
Bakheit, Ahmed H., Darwish, Hany, Darwish, Ibrahim A., Al-Ghusn, Ahmed I.   +3 more
  +17 more sources

Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions [PDF]

Journal of Pharmacy & Pharmaceutical Sciences, 2021
Purpose: Remdesivir, a drug originally developed against Ebola virus, is currently recommended for patients hospitalized with coronavirus disease of 2019 (COVID-19).
Subrata Deb, Anthony Allen Reeves
doaj   +3 more sources

Identification of bradycardia following remdesivir administration through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project [PDF]

, 2023
IMPORTANCE: The rapid spread and mortality associated with COVID-19 emphasized a need for surveillance system development to identify adverse events (AEs) to emerging therapeutics.
Abston, Stephanie, Aldy, Kim, Brent, Jeffrey, Burkhart, Keith, Campleman, Sharan, Devgun, Jason M, Meyn, Alison, Toxicology Investigators Consortium FACT Study Group,, Wax, Paul, Zhang, Rongmei   +9 more
core   +7 more sources

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

Nature Communications, 2021
Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients. The active form of remdesivir acts as a nucleoside analog and inhibits the RNA-dependent RNA polymerase (RdRp) of coronaviruses including SARS-CoV-2.
Goran Kokic, Hauke S Hillen, Dimitry Tegunov   +2 more
exaly   +2 more sources

Remdesivir for the Treatment of Covid-19 — Final Report

New England Journal of Medicine, 2020
Background Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.
John H Beigel, Lori E Dodd, Aneesh K Mehta   +2 more
exaly   +2 more sources

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Nature Communications, 2020
Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease associated with more than 2468 human infections and over 851 deaths in 27 countries since 2012.
Timothy P Sheahan, Sarah R Leist, Alexandra Schäfer   +2 more
exaly   +2 more sources

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Cell Research, 2020
Dear Editor, In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million people in central China. The initial cases were linked to exposures in a seafood market in Wuhan.
Manli Wang, Lei-Ke Zhang, Jia Liu
exaly   +2 more sources